• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对分枝杆菌感染的宿主导向治疗。

Host-directed therapy to combat mycobacterial infections.

机构信息

Department of Infectious Diseases, Leiden University Medical Center, Leiden, The Netherlands.

出版信息

Immunol Rev. 2021 May;301(1):62-83. doi: 10.1111/imr.12951. Epub 2021 Feb 9.

DOI:10.1111/imr.12951
PMID:33565103
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8248113/
Abstract

Upon infection, mycobacteria, such as Mycobacterium tuberculosis (Mtb) and nontuberculous mycobacteria (NTM), are recognized by host innate immune cells, triggering a series of intracellular processes that promote mycobacterial killing. Mycobacteria, however, have developed multiple counter-strategies to persist and survive inside host cells. By manipulating host effector mechanisms, including phagosome maturation, vacuolar escape, autophagy, antigen presentation, and metabolic pathways, pathogenic mycobacteria are able to establish long-lasting infection. Counteracting these mycobacteria-induced host modifying mechanisms can be accomplished by host-directed therapeutic (HDT) strategies. HDTs offer several major advantages compared to conventional antibiotics: (a) HDTs can be effective against both drug-resistant and drug-susceptible bacteria, as well as potentially dormant mycobacteria; (b) HDTs are less likely to induce bacterial drug resistance; and (c) HDTs could synergize with, or shorten antibiotic treatment by targeting different pathways. In this review, we will explore host-pathogen interactions that have been identified for Mtb for which potential HDTs impacting both innate and adaptive immunity are available, and outline those worthy of future research. We will also discuss possibilities to target NTM infection by HDT, although current knowledge regarding host-pathogen interactions for NTM is limited compared to Mtb. Finally, we speculate that combinatorial HDT strategies can potentially synergize to achieve optimal mycobacterial host immune control.

摘要

在感染后,分枝杆菌(如结核分枝杆菌(Mtb)和非结核分枝杆菌(NTM))被宿主固有免疫细胞识别,触发一系列促进分枝杆菌杀伤的细胞内过程。然而,分枝杆菌已经开发出多种对抗策略来在宿主细胞内持续存在和生存。通过操纵宿主效应机制,包括吞噬体成熟、空泡逃逸、自噬、抗原呈递和代谢途径,致病性分枝杆菌能够建立持久的感染。通过宿主定向治疗(HDT)策略可以对抗这些分枝杆菌诱导的宿主修饰机制。与传统抗生素相比,HDT 具有几个主要优势:(a)HDT 可有效对抗耐药和敏感细菌,以及潜在休眠的分枝杆菌;(b)HDT 不太可能诱导细菌耐药性;(c)HDT 可以通过靶向不同途径与抗生素协同作用或缩短抗生素治疗时间。在这篇综述中,我们将探讨已确定的针对 Mtb 的宿主-病原体相互作用,其中有针对先天和适应性免疫的潜在 HDT 可用,并概述那些值得进一步研究的相互作用。我们还将讨论通过 HDT 靶向 NTM 感染的可能性,尽管与 Mtb 相比,目前对 NTM 的宿主-病原体相互作用的了解有限。最后,我们推测组合 HDT 策略可能会协同作用,以实现最佳的分枝杆菌宿主免疫控制。

相似文献

1
Host-directed therapy to combat mycobacterial infections.针对分枝杆菌感染的宿主导向治疗。
Immunol Rev. 2021 May;301(1):62-83. doi: 10.1111/imr.12951. Epub 2021 Feb 9.
2
Autophagy and Host Defense in Nontuberculous Mycobacterial Infection.非结核分枝杆菌感染中的自噬与宿主防御
Front Immunol. 2021 Sep 6;12:728742. doi: 10.3389/fimmu.2021.728742. eCollection 2021.
3
Host-directed therapy with amiodarone in preclinical models restricts mycobacterial infection and enhances autophagy.在临床前模型中,使用胺碘酮进行宿主导向治疗可限制分枝杆菌感染并增强自噬。
Microbiol Spectr. 2024 Aug 6;12(8):e0016724. doi: 10.1128/spectrum.00167-24. Epub 2024 Jun 25.
4
FDA-Approved Amoxapine Effectively Promotes Macrophage Control of Mycobacteria by Inducing Autophagy.FDA 批准的阿莫沙平通过诱导自噬有效促进巨噬细胞控制分枝杆菌。
Microbiol Spectr. 2022 Oct 26;10(5):e0250922. doi: 10.1128/spectrum.02509-22. Epub 2022 Sep 21.
5
Nontuberculous Mycobacteria, Macrophages, and Host Innate Immune Response.非结核分枝杆菌、巨噬细胞和宿主固有免疫应答。
Infect Immun. 2021 Jul 15;89(8):e0081220. doi: 10.1128/IAI.00812-20.
6
Modulating macrophage function to reinforce host innate resistance against complex infection.调节巨噬细胞功能以增强宿主固有抵抗力对抗复杂感染。
Front Immunol. 2022 Nov 24;13:931876. doi: 10.3389/fimmu.2022.931876. eCollection 2022.
7
Drosophila versus Mycobacteria: A model for mycobacterial host-pathogen interactions.果蝇与分枝杆菌:分枝杆菌宿主-病原体相互作用的模型
Mol Microbiol. 2022 Mar;117(3):600-609. doi: 10.1111/mmi.14819. Epub 2021 Oct 20.
8
Dimethyl itaconate is effective in host-directed antimicrobial responses against mycobacterial infections through multifaceted innate immune pathways.衣康酸二甲酯通过多方面的固有免疫途径,在针对分枝杆菌感染的宿主导向性抗菌反应中有效。
Cell Biosci. 2023 Mar 8;13(1):49. doi: 10.1186/s13578-023-00992-x.
9
Harnessing host-pathogen interactions for innovative drug discovery and host-directed therapeutics to tackle tuberculosis.利用宿主-病原体相互作用进行创新药物发现和宿主导向治疗以应对结核病。
Microbiol Res. 2023 Oct;275:127466. doi: 10.1016/j.micres.2023.127466. Epub 2023 Jul 29.
10
Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches.结核病的宿主导向治疗:定量系统药理学方法。
Trends Pharmacol Sci. 2022 Apr;43(4):293-304. doi: 10.1016/j.tips.2021.11.016. Epub 2021 Dec 13.

引用本文的文献

1
Autophagy in mycobacterial infections: molecular mechanisms, host-pathogen interactions, and therapeutic opportunities.分枝杆菌感染中的自噬:分子机制、宿主-病原体相互作用及治疗机遇
Front Cell Infect Microbiol. 2025 Aug 7;15:1640647. doi: 10.3389/fcimb.2025.1640647. eCollection 2025.
2
The Parkinson's drug benztropine possesses histamine receptor 1-dependent host-directed antimicrobial activity against Mycobacterium tuberculosis.治疗帕金森病的药物苯海索具有依赖组胺受体1的针对结核分枝杆菌的宿主导向抗菌活性。
NPJ Antimicrob Resist. 2025 Aug 4;3(1):70. doi: 10.1038/s44259-025-00143-x.
3
Endogenous hepcidin plays an essential role in Rv1876 antigen-induced antimicrobial activity in macrophages.

本文引用的文献

1
HIV Skews a Balanced Mtb-Specific Th17 Response in Latent Tuberculosis Subjects to a Pro-inflammatory Profile Independent of Viral Load.HIV 使潜伏性结核病患者的 Mtb 特异性 Th17 反应向促炎表型倾斜,而与病毒载量无关。
Cell Rep. 2020 Dec 1;33(9):108451. doi: 10.1016/j.celrep.2020.108451.
2
The potential impact of the COVID-19 pandemic on the tuberculosis epidemic a modelling analysis.2019年冠状病毒病大流行对结核病流行的潜在影响:一项建模分析
EClinicalMedicine. 2020 Oct 24;28:100603. doi: 10.1016/j.eclinm.2020.100603. eCollection 2020 Nov.
3
[Meta-analysis of efficacy and safety of vitamin D supplementation in the treatment of pulmonary tuberculosis].
内源性铁调素在巨噬细胞中Rv1876抗原诱导的抗菌活性中起重要作用。
Emerg Microbes Infect. 2025 Dec;14(1):2539192. doi: 10.1080/22221751.2025.2539192. Epub 2025 Aug 6.
4
Unveiling the potential of antimicrobial peptides to combat Mycobacterium tuberculosis.揭示抗菌肽对抗结核分枝杆菌的潜力。
Arch Microbiol. 2025 Jul 17;207(9):199. doi: 10.1007/s00203-025-04393-1.
5
Gut microbiota and tuberculosis infection: interaction and therapeutic potential.肠道微生物群与结核病感染:相互作用及治疗潜力
Gut Microbes. 2025 Dec;17(1):2531201. doi: 10.1080/19490976.2025.2531201. Epub 2025 Jul 14.
6
Natural flavonoids combat cytosolic MRSA by potentiating phagosome acidification.天然黄酮类化合物通过增强吞噬体酸化作用来对抗胞质型耐甲氧西林金黄色葡萄球菌。
Cell Commun Signal. 2025 Jun 2;23(1):259. doi: 10.1186/s12964-025-02252-6.
7
Targeting Autophagy as a Strategy for Developing New Host-Directed Therapeutics Against Nontuberculous Mycobacteria.以自噬为靶点开发抗非结核分枝杆菌新型宿主导向疗法的策略
Pathogens. 2025 May 13;14(5):472. doi: 10.3390/pathogens14050472.
8
Pathogenicity and virulence of ..的致病性和毒力
Virulence. 2025 Dec;16(1):2508813. doi: 10.1080/21505594.2025.2508813. Epub 2025 May 26.
9
An Antibody-Recruiting Molecule Enhances Fcγ Receptor-Mediated Uptake and Killing of Mycobacterial Pathogens by Macrophages.一种抗体招募分子增强巨噬细胞通过Fcγ受体介导的对分枝杆菌病原体的摄取和杀伤作用。
ACS Infect Dis. 2025 Jun 13;11(6):1563-1576. doi: 10.1021/acsinfecdis.5c00097. Epub 2025 May 1.
10
Innovative Strategies for Combating Multidrug-Resistant Tuberculosis: Advances in Drug Delivery Systems and Treatment.对抗耐多药结核病的创新策略:药物递送系统与治疗的进展
Microorganisms. 2025 Mar 24;13(4):722. doi: 10.3390/microorganisms13040722.
[维生素D补充剂治疗肺结核疗效与安全性的荟萃分析]
Zhonghua Yi Xue Za Zhi. 2020 Aug 25;100(32):2525-2531. doi: 10.3760/cma.j.cn112137-20200121-00146.
4
New insights into the evasion of host innate immunity by Mycobacterium tuberculosis.结核分枝杆菌逃避宿主固有免疫的新见解。
Cell Mol Immunol. 2020 Sep;17(9):901-913. doi: 10.1038/s41423-020-0502-z. Epub 2020 Jul 29.
5
Host sirtuin 2 as an immunotherapeutic target against tuberculosis.宿主 SIRT2 作为抗结核免疫治疗靶点。
Elife. 2020 Jul 22;9:e55415. doi: 10.7554/eLife.55415.
6
Antimycobacterial Effects of Everolimus in a Human Granuloma Model.依维莫司在人肉芽肿模型中的抗分枝杆菌作用
J Clin Med. 2020 Jun 29;9(7):2043. doi: 10.3390/jcm9072043.
7
Safety and efficacy of N-acetylcysteine in hospitalized patients with HIV-associated tuberculosis: An open-label, randomized, phase II trial (RIPENACTB Study).N-乙酰半胱氨酸治疗 HIV 相关结核病住院患者的安全性和有效性:一项开放标签、随机、二期试验(RIPENACTB 研究)。
PLoS One. 2020 Jun 26;15(6):e0235381. doi: 10.1371/journal.pone.0235381. eCollection 2020.
8
Potentiation of rifampin activity in a mouse model of tuberculosis by activation of host transcription factor EB.宿主转录因子 EB 的激活增强了结核分枝杆菌小鼠模型中利福平的活性。
PLoS Pathog. 2020 Jun 23;16(6):e1008567. doi: 10.1371/journal.ppat.1008567. eCollection 2020 Jun.
9
Targeting bedaquiline mycobacterial efflux pump to potentially enhance therapy in abscessus.针对脓肿分枝杆菌外排泵的靶向治疗,可能增强其治疗效果。
Int J Mycobacteriol. 2020 Jan-Mar;9(1):71-75. doi: 10.4103/ijmy.ijmy_181_19.
10
Immunometabolism during Mycobacterium tuberculosis Infection.结核分枝杆菌感染期间的免疫代谢。
Trends Microbiol. 2020 Oct;28(10):832-850. doi: 10.1016/j.tim.2020.04.010. Epub 2020 May 11.